Delray Medical Center WATCHMAN FLX Device for Atrial Fibrillation Now Offered to Patients

Delray Medical Center now offers the WATCHMAN FLX™ for patients who have a high risk of stroke with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage-the area of the heart where stroke-causing blood clots commonly form in NAVF.

Delray Medical Center Dr. Martin Kloosterman, electrophysiologist on staff said, “People with atrial fibrillation are at an increased risk of stroke if they are not on blood thinners, which can also increase the risk of bleeding. This can often result in higher mortality and disability rates because of an injury to the brain or other affected areas.” He added, “We are pleased to have available a new generation of the Watchman FLX device, which expands the number of patients who can benefit from this life-saving technology.”

This technology features a new, fully rounded design offering physicians the ability to safely enter, and maneuver within the left atrial appendage.  It is the first LAAC device that can be fully recaptured, repositioned and redeployed for precise placement, and the new frame design allows for optimal device engagement with the tissue for long-term stability and a faster, more complete seal.

“This advanced technology gives us a new option to treat patients who are at high risk for stroke, that could also enable them to have a better long-term quality of life,” said Maggie Gill, chief executive officer for the Palm Beach Health Network and Delray Medical Center. “We remain committed to providing patients in Palm Beach County with comprehensive cardiovascular treatment options close to home, and in a safe environment.”

Atrial Fibrillation is a common heart disorder which occurs when electrical signals in the heart become irregular, causing the heart’s upper chamber to beat out of rhythm.  Atrial fibrillation requires immediate medical attention because it could lead to a life-threatening stroke, which is otherwise preventable.

When it comes to you, your family, and your health, Delray Medical Center and its cardiovascular team knows what it take to give you the care you need quickly and compassionately.  During a health emergency, you need health care you can trust.  At Delray Medical Center, we believe that is exactly what you will find.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”